Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation

• Autor: Gabitova, M. A. ; Krupenin, P. M. ; Sokolova, A. A. ; Napalkov, D. A. ; Fomin, V. V.
• Assuntos: apixaban ; atrial fibrillation ; bleeding ; dabigatran ; elderly ; non-vitamin k oral anticoagulants ; rivaroxaban
• É parte de: Rat͡s︡ionalʹnai͡a︡ farmakoterapii͡a︡ v kardiologii, 2020-01, Vol.15 (6), p.802-805
• Descrição: Aim. To study the safety of non-vitamin K oral anticoagulants (NOAC) in patients with atrial fibrillation (AF) over 75 years old.Material and methods. The observation study included patients ≥75 years of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full or reduced dosage. Previous experience of NOAC treatment from the very beginning of therapy, if a patient was ≥75 years old, or from the point a patient reached 75 years was considered; episodes of NOAK change, as well as hemorrhagic and ischemic events associated with taking an anticoagulant, were recorded. Patient groups were comparable in risk score by CHA2DS2-VASc and HAS-BLED scales.Results. Patients with AF (n=102; 39 men and 63 women; an average age 79.4Ѓ}4.1 years) were included: 32 patients were in dabigatran group, 34 patients – in apixaban group and 36 patients – in rivaroxaban group. 19 clinically significant bleedings were recorded, 10 occurred in patients taking dabigatran and 9 in those taking rivaroxaban. No hemorrhagic events in patients treated with apixaban were observed. Hematuria (31.6%), large subcutaneous hematomas (26.3%) and intensive nasal bleedings (26.3%) were the most frequent events. No ischemic cardioembolic stroke was recorded.Conclusions. In elderly patients, all NOAC (dabigatran, rivaroxaban and apixaban) demonstrated good safety profile without major bleeding within a 1.5-year follow-up period.
  
• Editor: Столичная издательская компания
  
• Idioma: Inglês